Oncology Corporate Profile
Vanquish Oncology is focused on developing targeted, small molecule oncology therapeutics for unmet or underserved cancer markets. Vanquish currently has an advanced program in selectively triggering cancer cell death through activating procaspase 3, a key late-stage effector of apoptosis. Vanquish is developing procaspase 3 activators as orally delivered therapies through a capital efficient virtual model that leverages contract research and manufacturing to minimize infrastructure outlays and overhead.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|PAC-1||procaspase activating compound-1||Various cancer types||I|